Critical levels of brain atrophy associated with homocysteine and cognitive decline

Related Experiment Video

Updated: Apr 28, 2026

Evaluation of the Cognitive Performance of Hypertensive Patients with Silent Cerebrovascular Lesions
07:30

Evaluation of the Cognitive Performance of Hypertensive Patients with Silent Cerebrovascular Lesions

Published on: April 23, 2021

2.6K

Celeste A de Jager1

  • 1Oxford Project to Investigate Memory and Ageing, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK.

Neurobiology of Aging
|June 15, 2014
PubMed

Insights

High homocysteine (Hcy) and brain atrophy may impair cognitive function in older adults. B-vitamin treatment efficacy depends on reaching critical levels of brain shrinkage and Hcy.

Area of Science:

  • Neurology
  • Nutritional Science
  • Gerontology

Background:

  • Elevated homocysteine (Hcy) is linked to cognitive decline and Alzheimer's disease.
  • Previous B-vitamin trials show limited success in improving cognition in older adults.
  • Meta-analyses often fail to demonstrate significant cognitive benefits from B-vitamin interventions.

Purpose of the Study:

  • To review the role of homocysteine in cognitive decline.
  • To explore reasons for the inefficacy of B-vitamin treatments in prior studies.
  • To re-examine the VITACOG trial data, considering critical levels of Hcy and brain atrophy.

Main Methods:

  • Review of existing literature on homocysteine, B-vitamins, and cognition.
  • Analysis of findings from the VITACOG trial.
  • Exploration of the relationship between brain atrophy, Hcy levels, and cognitive performance.

Main Results:

  • Cognitive decline, particularly in episodic memory, appears linked to critical levels of brain shrinkage.
  • Elevated homocysteine may mediate this brain shrinkage and subsequent cognitive impairment.
  • B-vitamin treatment efficacy might be dependent on the extent of brain atrophy and Hcy levels.

Conclusions:

  • A critical threshold of brain atrophy, potentially influenced by homocysteine, may determine cognitive decline.
  • Understanding these critical levels is crucial for optimizing B-vitamin treatment strategies.
  • Further research should consider individual Hcy levels and brain structure in relation to B-vitamin interventions for cognitive health.

Keywords:
Alzheimer's diseaseAtrophyB vitaminsB12 deficiencyCognitionFolic acidHomocysteineMild cognitive impairment

More Related Videos

Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans08:29

Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans

Published on: December 18, 2016

13.9K
Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains12:28

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

18.2K

Related Concept Videos

Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
20
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
32
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
31
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
Role of Neurotransmitters in Memory01:23

Role of Neurotransmitters in Memory

Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
 Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
2.8K
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
751